Mobile

APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemop...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002850-31

APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemopoietic stem cell transplantation

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objectives of this study are: 1. To asses the safety and the tolerability of 1 cycle of APO866, administered by continuous intravenous infusion, in patients with refractory B-cell chronic lymphocytic leukemia (B-CLL) non amenable to allogeneic hematopoietic stem cell transplantation (hASCT). 2. To evaluate the effect of APO866 on leukemic B-cells in this population of patients.

Critère d'inclusion

  • The medical condition for this clinical trial is B. cell chronic lymphocytic leukemia

Liens